Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Delays Phase III Trials Of AMG-706 Due To Cholecystitis Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Interim data from Phase II gastrointestinal stromal cancer trials showed 2%-3% of patients developed cholecystitis.

You may also be interested in...



Amgen Gets Panitumumab Priority Review

Amgen's panitumumab has an estimated mid-September user fee date under FDA priority review for metastatic colorectal cancer patients failing prior chemotherapy, the company announced June 12

Erbitux Pricing Could Be Modified With Longer Treatment Cycles

Cetuximab was approved March 1 for treatment of advanced head and neck cancer.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel